Prostate cancer treatment, prostate cancer brachytherapy

	1-877-DATTOLI (328-8654)

	Mapping the positioning of brachytherapy "seeds".

Without realizing it, every man who is treated at the Dattoli Cancer Center makes a valuable contribution to the next generation. Building upon their academic research backgrounds, Drs. Dattoli and Sorace continue to forge new inroads into the understanding of prostate cancer with each patient they see.

Detailed but non-identified statistics reflecting every facet of the patient's experience are entered into an on-going study. This endeavor is the largest and longest-standing examination of non-surgical treatment for prostate cancer anywhere in the literature. In conjunction with Dr. Kent Wallner of the University of Washington Medical Center, Seattle, an annual analysis is performed on the data to verify treatment efficacy and to prepare results calculations for publication.

Both Dr. Dattoli and Sorace are widely published in the field of prostate brachytherapy, enjoy national and international speaking invitations and are sought after to author chapters in medical texts. The quintessential reference on this treatment is Prostate Brachytherapy Made Complicated, co-authored by doctors Kent Wallner, John Blasko and Michael J. Dattoli.

The Dattoli Cancer Center & Brachytherapy Research Institute serves as one of the world's foremost research institutes in the treatment of prostate cancer using brachytherapy and combined modalities. Continuing to further define the role of the palladium isotope, either as the sole modality or in conjunction with with 4D IG-IMRT, comprises the Dattoli Team's greatest focus. In fact, the Dattoli program of integrating modern transperineal seeding with sophisticated beam radiation in the treatment of prostate cancer is the largest and most longstanding of its kind in the world.

At the Dattoli Cancer Center and Brachytherapy Research Institute, our focus in the clinical studies arena is to participate in research that will have a positive impact on the quality of life and survival of our patients seeking treatment for prostate cancer.

Currently we are involved in the Comprehensive, Observational, Multicenter Prostate Adenocarcinoma Registry (COMPARE) designed to collect data on the treatment of prostate cancer patients with a rising PSA. Physicians enrolling patients to this registry treat those individuals with their standard protocols and share information regarding response to therapy, time to disease progression and survival in what promises to become a national database which will undoubtedly lead to future research endeavors. In addition, we are conducting a retrospective chart analysis comparing the efficacy of Uroxatral and Flomax (both alpha-blockers) in the immediate post Palladium-103 brachytherapy period. Our goal with respect to research trials is to ask and perhaps answer questions that are important enough to have a direct impact on the individual patient.